ilv-095
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00822835)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-22INHIBITOR
IL22 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ilv-095
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01010542 | Phase 1 | Dec 1, 2009 | Pfizer |
| NCT00822484 | Phase 1 | Feb 1, 2009 | Pfizer |
| NCT00822835 | Phase 1 | Jan 1, 2009 | Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1